Search

Your search keyword '"Seksik P"' showing total 620 results

Search Constraints

Start Over You searched for: Author "Seksik P" Remove constraint Author: "Seksik P"
620 results on '"Seksik P"'

Search Results

1. Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

2. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

3. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trialsResearch in context

4. Urbanization associates with restricted gut microbiome diversity and delayed maturation in infants

5. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility

6. 3-oxo-C12:2-HSL, quorum sensing molecule from human intestinal microbiota, inhibits pro-inflammatory pathways in immune cells via bitter taste receptors

7. Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study

9. Insights into the genetic epidemiology of Crohns and rare diseases in the Ashkenazi Jewish population.

10. Circulating bile acids concentration is predictive of coronary artery disease in human

11. Fecal microbiota and bile acids in IBD patients undergoing screening for colorectal cancer

13. DOP26 Metagenomic and metabolomic profiles in IBD: understanding microbial and metabolic shifts from a large deeply phenotyped cohort

14. P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study

15. P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

16. DOP65 Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial

17. P903 Persistence, efficacy and tolerance of subcutaneous Infliximab after switch from intravenous infliximab in IBD patients in remission: one-year results from a multicenter prospective cohort

18. Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

20. Impact of IBD-Associated Dysbiosis on Bacterial Quorum Sensing Mediated by Acyl-Homoserine Lactone in Human Gut Microbiota

21. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

23. Lymphoma in Patients with Inflammatory Bowel Disease: A Multicentre Collaborative Study Between GETAID and LYSA.

24. Postprandial bile acid levels in intestine and plasma reveal altered biliary circulation in chronic pancreatitis patients

25. Impact of N-Acyl-Homoserine Lactones, Quorum Sensing Molecules, on Gut Immunity

26. Endoscopic Submucosal Dissection in Inflammatory Bowel Disease Patients for Visible Dysplasia: a French Retrospective Multicentric Study

27. Correction: Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population.

28. Genetic effects on the commensal microbiota in inflammatory bowel disease patients.

29. Saccharomyces boulardii CNCM I-745 Modulates the Fecal Bile Acids Metabolism During Antimicrobial Therapy in Healthy Volunteers

30. Anti-Inflammatory Effects of Analogues of N-Acyl Homoserine Lactones on Eukaryotic Cells

31. P404 Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission

33. Prevalence of Yersinia Species in the Ileum of Crohn's Disease Patients and Controls

34. Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population.

35. Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease.

36. Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota.

38. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands

39. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease

46. DOP33 Role of adherent and invasive E. coli in Crohn’s Disease: Lessons from the postoperative recurrence model

49. COMBIO : efficacité et tolérance des associations de thérapies ciblées chez les patients atteints de maladies inflammatoires à médiation immunitaire

Catalog

Books, media, physical & digital resources